Logo image of ACRS

ACLARIS THERAPEUTICS INC (ACRS) Stock Fundamental Analysis

NASDAQ:ACRS - US00461U1051 - Common Stock

1.81 USD
+0.01 (+0.56%)
Last: 8/26/2025, 8:13:50 PM
1.8173 USD
+0.01 (+0.4%)
After Hours: 8/26/2025, 8:13:50 PM
Fundamental Rating

3

Overall ACRS gets a fundamental rating of 3 out of 10. We evaluated ACRS against 193 industry peers in the Pharmaceuticals industry. ACRS has a great financial health rating, but its profitability evaluates not so good. ACRS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ACRS had negative earnings in the past year.
ACRS had a negative operating cash flow in the past year.
In the past 5 years ACRS always reported negative net income.
ACRS had a negative operating cash flow in each of the past 5 years.
ACRS Yearly Net Income VS EBIT VS OCF VS FCFACRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

ACRS has a Return On Assets of -71.19%. This is in the lower half of the industry: ACRS underperforms 67.88% of its industry peers.
Looking at the Return On Equity, with a value of -102.21%, ACRS is in line with its industry, outperforming 41.97% of the companies in the same industry.
Industry RankSector Rank
ROA -71.19%
ROE -102.21%
ROIC N/A
ROA(3y)-46.3%
ROA(5y)-49.43%
ROE(3y)-61.73%
ROE(5y)-73.31%
ROIC(3y)N/A
ROIC(5y)N/A
ACRS Yearly ROA, ROE, ROICACRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

Looking at the Gross Margin, with a value of 10.21%, ACRS is in line with its industry, outperforming 49.22% of the companies in the same industry.
In the last couple of years the Gross Margin of ACRS has grown nicely.
The Profit Margin and Operating Margin are not available for ACRS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.2%
GM growth 5Y35.7%
ACRS Yearly Profit, Operating, Gross MarginsACRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

7

2. Health

2.1 Basic Checks

ACRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ACRS has more shares outstanding
ACRS has more shares outstanding than it did 5 years ago.
ACRS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACRS Yearly Shares OutstandingACRS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ACRS Yearly Total Debt VS Total AssetsACRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

ACRS has an Altman-Z score of -5.32. This is a bad value and indicates that ACRS is not financially healthy and even has some risk of bankruptcy.
ACRS has a Altman-Z score of -5.32. This is comparable to the rest of the industry: ACRS outperforms 40.41% of its industry peers.
There is no outstanding debt for ACRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.32
ROIC/WACCN/A
WACC9.99%
ACRS Yearly LT Debt VS Equity VS FCFACRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

ACRS has a Current Ratio of 3.88. This indicates that ACRS is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 3.88, ACRS is doing good in the industry, outperforming 64.77% of the companies in the same industry.
ACRS has a Quick Ratio of 3.88. This indicates that ACRS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.88, ACRS is in the better half of the industry, outperforming 65.80% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.88
Quick Ratio 3.88
ACRS Yearly Current Assets VS Current LiabilitesACRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

ACRS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -67.07%.
The Revenue for ACRS has decreased by -47.56% in the past year. This is quite bad
Measured over the past years, ACRS shows a very strong growth in Revenue. The Revenue has been growing by 34.65% on average per year.
EPS 1Y (TTM)-67.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
Revenue 1Y (TTM)-47.56%
Revenue growth 3Y40.43%
Revenue growth 5Y34.65%
Sales Q2Q%-35.76%

3.2 Future

ACRS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.69% yearly.
ACRS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.48% yearly.
EPS Next Y65.21%
EPS Next 2Y28.05%
EPS Next 3Y16.18%
EPS Next 5Y8.69%
Revenue Next Year-51.79%
Revenue Next 2Y-31.16%
Revenue Next 3Y-18.64%
Revenue Next 5Y25.48%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ACRS Yearly Revenue VS EstimatesACRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
ACRS Yearly EPS VS EstimatesACRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ACRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACRS Price Earnings VS Forward Price EarningsACRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACRS Per share dataACRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

ACRS's earnings are expected to grow with 16.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.05%
EPS Next 3Y16.18%

More info and screens

0

5. Dividend

5.1 Amount

ACRS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACLARIS THERAPEUTICS INC

NASDAQ:ACRS (8/26/2025, 8:13:50 PM)

After market: 1.8173 +0.01 (+0.4%)

1.81

+0.01 (+0.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-04 2025-11-04/bmo
Inst Owners87.74%
Inst Owner Change-0.94%
Ins Owners2.58%
Ins Owner Change1.33%
Market Cap196.08M
Analysts84.29
Price Target8.01 (342.54%)
Short Float %6.22%
Short Ratio5.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.97%
Min EPS beat(2)-0.13%
Max EPS beat(2)4.07%
EPS beat(4)1
Avg EPS beat(4)-534.44%
Min EPS beat(4)-1788.67%
Max EPS beat(4)4.07%
EPS beat(8)5
Avg EPS beat(8)-247.68%
EPS beat(12)9
Avg EPS beat(12)-160.59%
EPS beat(16)12
Avg EPS beat(16)-119.32%
Revenue beat(2)2
Avg Revenue beat(2)19.17%
Min Revenue beat(2)11.41%
Max Revenue beat(2)26.93%
Revenue beat(4)3
Avg Revenue beat(4)81.65%
Min Revenue beat(4)-40.15%
Max Revenue beat(4)328.42%
Revenue beat(8)7
Avg Revenue beat(8)167.28%
Revenue beat(12)10
Avg Revenue beat(12)226.62%
Revenue beat(16)10
Avg Revenue beat(16)166.99%
PT rev (1m)0%
PT rev (3m)-22.97%
EPS NQ rev (1m)7.14%
EPS NQ rev (3m)13.33%
EPS NY rev (1m)5.38%
EPS NY rev (3m)8.44%
Revenue NQ rev (1m)6.17%
Revenue NQ rev (3m)-1.76%
Revenue NY rev (1m)-2.97%
Revenue NY rev (3m)9.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.68
P/FCF N/A
P/OCF N/A
P/B 1.49
P/tB 1.49
EV/EBITDA N/A
EPS(TTM)-1.37
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0.15
BVpS1.22
TBVpS1.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.19%
ROE -102.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.21%
FCFM N/A
ROA(3y)-46.3%
ROA(5y)-49.43%
ROE(3y)-61.73%
ROE(5y)-73.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.2%
GM growth 5Y35.7%
F-Score2
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6508.33%
Cap/Sales 218.64%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.88
Quick Ratio 3.88
Altman-Z -5.32
F-Score2
WACC9.99%
ROIC/WACCN/A
Cap/Depr(3y)1560.12%
Cap/Depr(5y)949.63%
Cap/Sales(3y)66.06%
Cap/Sales(5y)41.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-67.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
EPS Next Y65.21%
EPS Next 2Y28.05%
EPS Next 3Y16.18%
EPS Next 5Y8.69%
Revenue 1Y (TTM)-47.56%
Revenue growth 3Y40.43%
Revenue growth 5Y34.65%
Sales Q2Q%-35.76%
Revenue Next Year-51.79%
Revenue Next 2Y-31.16%
Revenue Next 3Y-18.64%
Revenue Next 5Y25.48%
EBIT growth 1Y-1.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.73%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.49%
OCF growth 3YN/A
OCF growth 5YN/A